InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
11%
T+90 mean return
-1.9%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Bowden Christopher, Director. Officer active across 4 companies, notably Ziopharm Oncology INC. Cumulatively, 11 disclosures have been published. History available since 4 March 2021. The latest transaction was filed on 22 June 2022 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations11 total
40,000 shares0Common StockSEC:0000899243-22-023978:0
1,885 shares@ US$39.7612.1% of flowCommon stockSEC:0001439222-21-000059
1,885 shares@ US$39.760.0038% mcap12.1% of flowCommon stockSEC:0001439222-21-000059:0
2,502 shares@ US$39.7616.1% of flowCommon stockSEC:0001439222-21-000058
2,502 shares@ US$39.760.0050% mcap16.1% of flowCommon stockSEC:0001439222-21-000058:0
7,149 shares@ US$39.7645.0% of flowCommon stockSEC:0001439222-21-000057
7,149 shares@ US$39.760.014% mcap45.0% of flowCommon stockSEC:0001439222-21-000057:0
4,268 shares@ US$39.760.0083% mcap26.8% of flowCommon stockSEC:0001439222-21-000056:0
4,268 shares@ US$39.7626.8% of flowCommon stockSEC:0001439222-21-000056
4,167 sharesCommon StockSEC:0001209191-21-030737
4,167 shares0Common StockSEC:0001209191-21-030737:0
11 of 11 declarations
About Bowden Christopher
Christopher Bowden is the Chief Medical Officer at ZIOPHARM ONCOLOGY INC and AGIOS PHARMACEUTICALS, INC. In this role, he oversees the company's medical and research initiatives. His expertise in the medical field is crucial for innovation and the development of new treatments.
